Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan's commitment to breakthrough therapies Funding will advance RegCell's first-in-class epigenetic regulatory T-cell reprogramming platform to first-in-human clinical trials in 2025 Strategic move to a U.
S.-based entity will accelerate clinical development, global partnerships, and commercialization opportunities for company founded by pioneering immunologist EMERYVILLE, Calif. , March 18, 2025 /PRNewswire/ -- RegCell, Inc.
, a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T-cells (Tregs), today announced the closing of an oversubscribed seed round and its transition to a U.S.-based company.
The $8.5 million seed financing was co-led by The University of Tokyo Edge Capital Partners (UTEC) and Fast Track Initiative (FTI), with participation from Celadon Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC), and Kyoto University Innovation Capital (Kyoto i-Cap). In addition, RegCell was awarded up to $37.
3 million in non-dilutive funding (¥5.6 Billion) from Japan's Agency for Medical Research and Development (AMED). This funding will support the development of RegCell's epigenetic reprogramming platform through clinical proof-of-co.
